ClinicalTrials.gg
CompletedNCT00191854Updated Mar 2, 2010Results posted

Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

A Phase 2 interventional study of gemcitabine and paclitaxel in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 18 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-02.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
93rd of 361
147 · median 60
Started
2005
with 16 others
Phase 2
205 of 373
20 open now
Registered
68th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 93rd largest by enrollment of the 361 interventional ones that give a count, is one of 17 that started in 2005, is one of 205 in phase 2, and was the 68th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined. The primary objective of this study is to compare the response rates of the gemcitabine-paclitaxel, gemcitabine-carboplatin, and gemcitabine-cisplatin combinations when administered on a biweekly schedule in metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with histological or cytological proven diagnosis of breast cancer
  • Stage IV disease
  • Performance Status of 0 or 1 on the (ECOG) Scale
  • Patients had to have previously received anthracycline based regimens as a therapy or neo-adjuvant chemotherapy and then progressed and developed disease
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy for disease
  • Previous radiation therapy is allowed but must not have included whole pelvis radiation
  • Known or suspected . Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
  • Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy and immunotherapy (including trastuzumab (Herceptin))
  • Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder, including seizures or dementia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Gemcitabine + Paclitaxel

    gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles. paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles.

    Drug: gemcitabine · Drug: paclitaxel

  • Experimental
    Gemcitabine + Carboplatin

    gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles. carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles.

    Drug: gemcitabine · Drug: carboplatin

  • Experimental
    Gemcitabine + Cisplatin

    gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles. cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles

    Drug: gemcitabine · Drug: cisplatin

Interventions

  • 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles

    Also known as: LY188011, Gemzar

  • 150 mg/m2, IV, every 14 days x 8 cycles

  • Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles

  • 50 mg/m2, IV, every 14 days x 8 cycles

06

What researchers measure

Primary outcomes

  1. Best Overall Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization)

Secondary outcomes

  1. Number of Participants With a Time to Treatment Failure (TTTF) Event

    TTTF event was defined as documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity. TTTF for patients who were still participating in study without treatment failure at time of analysis were treated as censored at date of last tumor assessment. TTTF for patients who had discontinued from therapy for reasons other than toxicity and who did not experience treatment failure prior to therapy discontinuation were treated as censored on day of study discontinuation.

    Time frame: randomization to date of documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity, whichever occurred first (up to 6 months)

  2. Progression Free Survival (PFS)

    PFS was defined as the time from randomizaton to the date of documented disease progression or death on study, whichever occurred first. PFS for participants who discontinued from the study or who had not progressed at the time of analysis were treated as censored at the date of the last tumor assessment.

    Time frame: baseline to measured progressive disease or death (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death, or up to 24 months after randomization)

  3. Duration of Response

    Duration of response was measured from time of first documentation of complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions), until date of PFS. Duration of response was censored on day of last tumor assessment for patients who had not progressed or who had discontinued study at time of analysis, and for cases where investigator determined patient had progressive disease and discontinued study therapy and/or started a new, non-protocol-specified anti-cancer therapy before documented disease progression.

    Time frame: time of response to progressive disease or death (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death, or up to 24 months after randomization)

  4. Overall Survival

    Overall survival time is defined as the time from the date of randomization to date of death due to any cause. Survival time is censored at the date of last contact for patients who are still alive or lost to follow-up.

    Time frame: baseline to date of death from any cause (up to 34 months)

07

Results

Posted Aug 31, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
Started494751
Received at least one dose of study drug494750
Completed121712
Not completed373039
Withdrew: Death262329
Withdrew: Lost to follow-up755
Withdrew: Withdrawal by subject423
Withdrew: Sponsor decision001
Withdrew: Screen failure001

Outcome measures

PrimaryBest Overall Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization)
Reported as:
Number · participants
Best Overall Response
participantsGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
Complete Response (CR)101
Partial Response (PR)1287
Stable Disease (SD)172529
Progressive Disease (PD)141111
Early Death from Other Causes120
Unknown413
SecondaryNumber of Participants With a Time to Treatment Failure (TTTF) Event

TTTF event was defined as documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity. TTTF for patients who were still participating in study without treatment failure at time of analysis were treated as censored at date of last tumor assessment. TTTF for patients who had discontinued from therapy for reasons other than toxicity and who did not experience treatment failure prior to therapy discontinuation were treated as censored on day of study discontinuation.

Time frame:
randomization to date of documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity, whichever occurred first (up to 6 months)
Reported as:
Number · participants
Number of Participants With a Time to Treatment Failure (TTTF) Event
participantsGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
Number of Participants With a Time to Treatment Failure (TTTF) Event152121
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from randomizaton to the date of documented disease progression or death on study, whichever occurred first. PFS for participants who discontinued from the study or who had not progressed at the time of analysis were treated as censored at the date of the last tumor assessment.

Time frame:
baseline to measured progressive disease or death (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death, or up to 24 months after randomization)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
Progression Free Survival (PFS)4.8 (4.2 to 7.0)4.3 (3.7 to 5.9)4.8 (3.7 to 8.1)
SecondaryDuration of Response

Duration of response was measured from time of first documentation of complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions), until date of PFS. Duration of response was censored on day of last tumor assessment for patients who had not progressed or who had discontinued study at time of analysis, and for cases where investigator determined patient had progressive disease and discontinued study therapy and/or started a new, non-protocol-specified anti-cancer therapy before documented disease progression.

Time frame:
time of response to progressive disease or death (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death, or up to 24 months after randomization)
Reported as:
Median · months
Duration of Response
monthsGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
Duration of Response5.8 (4.9 to 8.1)3.2 (1.9 to 5.0)5.1 (2.9 to 5.1)
SecondaryOverall Survival

Overall survival time is defined as the time from the date of randomization to date of death due to any cause. Survival time is censored at the date of last contact for patients who are still alive or lost to follow-up.

Time frame:
baseline to date of death from any cause (up to 34 months)
Reported as:
Median · months
Overall Survival
monthsGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
Overall Survival15.5 (0.361 to 33.84)22.8 (1.413 to 26.12)20.1 (1.413 to 27.83)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine + Paclitaxel—5/49 (10.2%)48/49 (98%)
Gemcitabine + Carboplatin—3/47 (6.4%)46/47 (97.9%)
Gemcitabine + Cisplatin—0/50 (0%)50/50 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
NeutropeniaBlood and lymphatic system disorders0/491/470/50
ThrombocytopeniaBlood and lymphatic system disorders1/491/470/50
Hepatic failureHepatobiliary disorders0/491/470/50
PneumoniaInfections and infestations0/491/470/50
PyelonephritisInfections and infestations0/491/470/50
SepsisInfections and infestations0/491/470/50
Haemoglobin decreasedInvestigations0/491/470/50
Renal failure acuteRenal and urinary disorders0/491/470/50
DyspnoeaRespiratory, thoracic and mediastinal disorders1/491/470/50
Pleural effusionRespiratory, thoracic and mediastinal disorders0/491/470/50
Most frequent other events
Showing 10 of 49
Most frequent other events
EventGemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + Cisplatin
NauseaGastrointestinal disorders19/4925/4739/50
VomitingGastrointestinal disorders12/4922/4731/50
AlopeciaSkin and subcutaneous tissue disorders25/4916/4722/50
Neutrophil count decreasedInvestigations22/4914/4721/50
Alanine aminotransferase increasedInvestigations18/4920/478/50
Haemoglobin decreasedInvestigations15/4918/4718/50
Platelet count decreasedInvestigations7/4918/477/50
FatigueGeneral disorders18/4917/4715/50
White blood cell count decreasedInvestigations17/4913/4713/50
AnorexiaMetabolism and nutrition disorders11/4915/478/50

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
Mean49.8 ± 8.846.0 ± 6.949.2 ± 10.348.4 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
Female494751147
Male0000
Region of Enrollment
Region of Enrollment(participants)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
Mexico1236
Brazil55414
Turkey52411
China25252676
Korea, Republic of55616
India88824
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
0 - Fully Active22292677
1 - Ambulatory, Restricted Strenuous Activity27182469
Missing Data0011
Menopausal Status
Menopausal Status(participants)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
Pre-Menopausal11161340
Peri Menopausal44412
Post Menopausal34263393
Missing Data0112
Pathological Diagnosis
Pathological Diagnosis(participants)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
Adenocarcinoma1225
Carcinoma, Infiltrating Ductal424045127
Carcinoma, Infiltrating Lobular64212
Carcinoma, Undifferentiated0101
Comedocarcinoma0011
Missing Data0011
Race/Ethnicity
Race/Ethnicity(participants)Gemcitabine + PaclitaxelGemcitabine + CarboplatinGemcitabine + CisplatinTotal
African1012
Caucasian86721
East Asian30303292
Hispanic2338
West Asian (West Indian)88824
08

Study locations

18 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santo André, 09060-020, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Paulo, 05403-900, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100071, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310016, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nan Jing, 210009, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Delhi, 110085, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kolkata, 700053, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ludhiana, 141001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400016, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pune, 411001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 138-736, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cuernavaca, 62200, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 01120, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Villahermosa, 86090, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Antalya, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gaziantep, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kayseri, 38039, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Aug 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Mar 2005
Primary completionActual
Aug 2008
CompletionActual
Nov 2009
Results first posted
Aug 31, 2009
Last update
Mar 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191854
First posted
Sep 19, 2005
Start date
Mar 2005
Primary completion
Aug 2008
Completion
Nov 2009
Results posted
Aug 31, 2009
Last update
Mar 2, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Monday-Friday 9:00 AM to 5:00 PM Est Time (UTC/GMT - 5 hours)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Carboplatin · Cisplatin

Start the discussion